不适合手术切除的乳腺癌患者的局部消融放疗
该回顾性分析纳入2014至2021年不适合切除的57例乳腺癌患者共61个疗程,接受35至40 Gy/5次消融放疗。2年局部失败累积发生率为11.4%,≥3级毒性为15.1%,均为放射性皮炎。作者认为该方案安全有效,高度适形技术(IMRT或部分乳腺照射)与毒性风险降低相关。
要点
- 35至40 Gy/5次消融放疗的2年局部失败累积发生率为11.4%,≥3级毒性为15.1%。
- 全部≥3级毒性均为放射性皮炎,未观察到臂丛神经病变。
- IMRT治疗≥3级毒性为6.5%,非IMRT全乳腺治疗为38.9%(HR 6.91,P = .023)。
核心结论
- 35至40 Gy/5次是安全有效的乳腺立体定向体部放疗方案,可能是不适合手术患者的有吸引力的选择。
- 高度适形技术(即IMRT或部分乳腺照射)与毒性风险降低相关,应作为首选治疗方式。
研究设计与样本
- 本研究为回顾性分析,数据来自机构登记库,纳入2014至2021年不适合切除且接受35至40 Gy/5次原发乳腺肿瘤或区域淋巴结放疗的乳腺癌患者。
- 共回顾57例患者、61个治疗疗程,中位年龄81岁(范围38至99岁)。
主要发现
- 未手术原因包括不可切除肿瘤(10%)、患者拒绝(18%)、医学上不能手术(35%)和转移性疾病(37%)。
- 5例(8%)既往接受过辅助局部区域放疗。
- 54%(n = 33/61)的疗程仅照射乳腺,31%(n = 19/61)照射乳腺和淋巴结,15%(n = 9/61)仅照射淋巴结。
- 照射乳腺的疗程中,67%(n = 35/52)采用部分乳腺照射,33%(n = 17/52)采用全乳腺放疗(中位剂量25 Gy/5次)±原发肿瘤同步整合推量。
- 多数原发肿瘤(65%,n = 34/52)和靶区淋巴结(61%,n = 17/28)接受35 Gy/5次剂量。
关键数值与推荐
- 2年局部失败累积发生率为11.4%,≥3级毒性累积发生率为15.1%。
- IMRT治疗≥3级毒性为6.5%,非IMRT治疗部分乳腺或淋巴结为7.7%(HR 1.13,P = .92),非IMRT治疗全乳腺为38.9%(HR 6.91,P = .023)。
- 所有≥3级毒性均为放射性皮炎;未观察到臂丛神经病变。
临床怎么用
- 作者认为35至40 Gy/5次是安全有效的乳腺SBRT方案,可能是不适合手术患者的有吸引力的选择。
- 作者建议高度适形技术(即IMRT或部分乳腺照射)应作为首选治疗方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with breast cancer who are unsuitable for surgical resection are typically managed with palliative systemic therapy alone. We report outcomes of 5-fraction ablative radiation therapy for nonresected breast cancers. METHODS AND MATERIALS: This is a retrospective analysis of an institutional registry of patients with breast cancer who were unsuitable for resection and underwent 35 to 40 Gy/5 fractions to the primary breast tumor or regional lymph nodes from 2014 to 2021. Primary outcomes were cumulative incidence of local failure and grade ≥3 toxicity (Common Terminology Criteria for Adverse Events, version 5.0). RESULTS: We reviewed 57 patients who received 61 treatment courses (median age of 81 years; range, 38-99). Unresectable tumor (10%), patient refusal (18%), medical inoperability (35%), and metastatic disease (37%) were the causes of not having surgery. Five patients (8%) had previously undergone adjuvant locoregional radiation therapy. Fifty-four percent (n = 33/61) of treatment courses targeted the breast only, 31% (n = 19/61) both the breast and lymph nodes, and 15% (n = 9/61) the lymph nodes only. Sixty-seven percent (n = 35/52) of the courses that targeted the breast were delivered with partial breast irradiation and 33% (n = 17/52) with whole breast radiation therapy (median dose of 25 Gy in 5 fractions) ± simultaneous integrated boost to the primary tumor. Most primary tumors (65%, n = 34/52) and target lymph nodes (61%, n = 17/28) were treated with a dose of 35 Gy in 5 fractions. Most treatments (52%) were delivered with intensity modulated radiation therapy (IMRT). Radiation therapy was delivered daily (20%), every other day (18%), twice weekly (36%), or weekly (26%). The 2-year cumulative incidence of local failure was 11.4% and grade≥3 toxicity was 15.1%. The grade ≥3 toxicity was 6.5% for IMRT treatments, versus 7.7% for non-IMRT treatments targeting partial breast or lymph nodes (hazard ratio, 1.13, P = .92), versus 38.9% for non-IMRT treatments targeting the entire breast (hazard ratio, 6.91, P = .023). All grade ≥3 toxicity cases were radiation dermatitis. No cases of brachial plexopathy were observed. CONCLUSIONS: Thirty-five to 40 Gy in 5 fractions is a safe and effective breast stereotactic body radiation therapy (SBRT) regimen and may be an attractive option for patients who are not surgical candidates. Highly conformal techniques (ie, IMRT or partial breast irradiation) were associated with a reduced risk of toxicity and should be the preferred treatment approaches.
引用
- Moore-Palhares D, Chen H, Khan BM, et al. Locoregional Ablative Radiation Therapy for Patients With Breast Cancer Unsuitable for Surgical Resection. Pract Radiat Oncol. 2023. PMID: 38154688. doi:10.1016/j.prro.2023.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。